Abstract
Elacestrant, a novel oral selective estrogen receptor (ER) degrader (SERD), was approved by the Food and Drug Administration (FDA) on January 27, 2023......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
